Vorinostat and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase I trial is studying the side effects and best dose of vorinostat when given
together with bortezomib in treating patients with relapsed or refractory multiple myeloma.
Vorinostat and bortezomib may stop the growth of cancer cells by blocking some of the enzymes
needed for cell growth. Giving vorinostat together with bortezomib may kill more cancer cells